ArticleAmerican journal of respiratory and critical care medicine2026
Post-tuberculosis lung disease in treated extra-pulmonary tuberculosis.
Article in American journal of respiratory and critical care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
backgroundPost-tuberculosis lung disease is a well-recognized sequela of pulmonary tuberculosis (PTB). Extra-PTB (EPTB) accounts for a quarter of the global TB burden; yet pulmonary sequelae in people treated for EPTB are unknown.
methodsWe performed spirometry at successful treatment completion and semi-annually thereafter for 1.5 years, among adults (aged 18 years and older) with drug-sensitive PTB and EPTB recruited from outpatient clinics in India. Adult household contacts without current TB disease underwent spirometry at enrollment and served as non-TB controls. Logistic and linear regression was used to measure the association of treated EPTB with ventilatory defects and persistence of impaired lung function during posttreatment follow-up, respectively.
resultsWe enrolled 775 TB survivors; 275 (35%) of whom were treated for EPTB and 502 non-TB controls. Compared to controls, EPTB was associated with lower z scores for FEV1 (-0.37; 95% CI, -0.54 to -0.20; P < .001) and FVC (-0.46; 95% CI, -0.65 to -0.26; P < .001) and higher odds of airflow obstruction (adjusted odds ratio [aOR] = 1.58; 95% CI, 0.95-2.61; P = .066) and restrictive spirometry (aOR = 2.16; 95% CI, 1.48-3.15; P < .001) at treatment completion. Lung function deficits in EPTB survivors persisted during the 1.5 years of posttreatment follow-up and were associated with respiratory symptoms. Findings were consistent in sensitivity analyses accounting for misclassified EPTB and unmeasured confounders. Ventilatory defects in treated EPTB were phenotypically comparable to those seen in treated PTB, however their burden, severity, and likelihood of respiratory symptoms were lower.
conclusionPeople treated for EPTB have persistent ventilatory defects and respiratory symptoms and should be screened for post-TB lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.